glp 1 conversion chart Injectable GLP-1 Receptor Agonists Switching Between Glucagon-Like Peptide-1 Receptor

A major growth factor for Saxenda is the increasing awareness and emphasis on obesity as a medical condition requiring pharmacological intervention alongside lifestyle modifications

28 Relative to placebo, GLP-1RA therapy was associated with significant (65%) reduction in major CV event with an odds ratio (OR) of 0.51 (95% CI 0.28, 0.93

Rapid weight reductioncommon in the first months of treatment with these medicationsmay not allow sufficient time for physiological adaptation

Rapid weight reduction may involve mobilization of glycogen stores and associated water weight

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

"GI AEs typically occur during initiation and uptitration, appearing as transient, mild-to-moderate symptoms." Laura Schalliol, PharmD, BCACP, BCGP, Professor of Pharmacy Practice In fact, 94% of adverse events reported in major clinical trials were mild or moderate in severity